MedTrace Logo

Rapid Atrial Fibrillation Treatment Strategy

NCT04092621 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-09-17

No results posted yet for this study

Summary

Prospective, randomized, open-label clinical trial studying the treatment of new onset atrial fibrillation in critically ill patients with septic shock. Patients will be assigned to rhythm vs rate control strategies with various outcome measures assessed.

Conditions

Interventions

DRUG

Amiodarone in Parenteral Dosage Form

Amiodarone IV

DRUG

Amiodarone Pill

Amiodarone tablet

PROCEDURE

Direct Current Cardioversion (DCC)

Convert arrhythmia back to sinus rhythm

DRUG

Rate-control therapy

one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin

Sponsors & Collaborators

  • Our Lady of the Lake Hospital

    lead OTHER

Principal Investigators

  • Hollis R O'Neal, MD · Louisiana State University Health Sciences Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2020-09-15
Completion
2020-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04092621 on ClinicalTrials.gov